Impact of geographical and cultural factors on clinical trials in acute mania: Lessons from a ziprasidone and haloperidol placebo-controlled study

International Journal of Neuropsychopharmacology

Volumn 14, Issue 8, 2011, Pages 1017-1027

  Vieta, Eduard ^a   Pappadopulos, Elizabeth ^b   Mandel, Francine S ^b   Lombardo, Ilise ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b PFIZER INC   (United States)

Author keywords

Bipolar mania; clinical design; geography; placebo response

Indexed keywords

HALOPERIDOL; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CULTURAL FACTOR; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GEOGRAPHY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MANIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RUSSIAN FEDERATION; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CULTURAL CHARACTERISTICS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; INDIA; INTERNATIONALITY; MALE; PIPERAZINES; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RUSSIA; THIAZOLES; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 80052969958     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571100040X     Document Type: Article

References (14)

1. El Mallakh RS, Vieta E, Rollin L, Marcus R, et al. (2010). A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 20, 776-783.
2. Han PY, Duffull SB, Kirkpatrick CM, Green B (2007). Dosing in obesity: a simple solution to a big problem. Clinical Pharmacology and Therapeutics 82, 505-508. (Pubitemid 47622534)
3. Khanna S, Vieta E, Lyons B, Grossman F, et al. (2005). Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. British Journal of Psychiatry 187, 229-234. (Pubitemid 41306103)
4. Platonov P (2003). Clinical trials in Russia and Eastern Europe: recruitment and quality. Interational Journal of Clinical Pharmacology and Therapeutics 41, 277-280. (Pubitemid 36869256)
5. Raja S, Wood SK, de M V, Mannarath SC (2010). Mapping mental health finances in Ghana, Uganda, Sri Lanka, India and Lao PDR. International Journal of Mental Health System 4, 11.
6. Shah JY, Phadtare A, Rajgor D, Vaghasia M, et al. (2010). What leads Indians to participate in clinical trials? A meta-analysis of qualitative studies. PLoS One 5, e10730.
7. Sysko R, Walsh BT (2007). A systematic review of placebo response in studies of bipolar mania. Journal of Clinical Psychiatry 68, 1213-1217. (Pubitemid 47395623)
8. Vieta E, Carne X (2005). The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychotherapy and Psychosomatics 74, 10-16. (Pubitemid 40091413)
9. Vieta E, Cruz N (2008). Increasing rates of placebo response over time in mania studies. Journal of Clinical Psychiatry 69, 681-682. (Pubitemid 351792352)
10. Vieta E, Ramey T, Keller D, English P, et al. (2010). Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. Journal of Psychopharmacology 24, 547-558.
11. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression: variable, substantial, and growing. Journal of the American Medical Association 287, 1840-1847. (Pubitemid 34303629)
12. Walsh BT, Sysko R (2005). Placebo control groups in trials of major depressive disorder among older patients. Journal of Clinical Psychopharmacology 25 (4 Suppl. 1), S29-S33. (Pubitemid 41060244)
13. Watsky EJ, Schwartz JH, Kremer CME (2009). The impact of geography on precision in clinical trials: experience with placebo and an active control in a phase 2a study in patients with acute symptoms of schizophrenia. Presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) 2009 Autumn Conference, 5-6 October 2009, San Diego, CA.
14. Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64, 663-667. (Pubitemid 36750143)